Ravulizumab for Generalized Myasthenia Gravis in Chinese Adults
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with generalized myasthenia gravis (gMG) for at least 6 months with confirmed antibody test
- Moderate-to-severe MG symptoms (MGFA Class II–IV) and a symptom score of 6 or higher at screening
- Up-to-date meningococcal vaccination (within 3 years) to prevent serious infection risk
- Weigh at least 40 kg (approximately 88 pounds)
- No untreated thymic cancer, active serious infections, HIV, hepatitis B or C, or recent hospitalization (≥24 hours within 4 weeks)
- Normal or near-normal liver and kidney function, and not currently using certain immune therapies (complement inhibitors, FcRn inhibitors, rituximab, or ongoing plasma exchange)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
This study is for people with generalized myasthenia gravis who are already on ravulizumab and a daily steroid. It aims to see if the steroid dose can be safely lowered over time.
This study tests a new drug called gefurulimab in children and teens with generalized myasthenia gravis (a disease that causes muscle weakness). It looks at how safe and effective the drug is, and how it works in the body.
This trial tests a new medication (remibrutinib) versus a placebo to see if it helps adults with generalized myasthenia gravis. You may qualify if your symptoms affect multiple parts of your body and you haven't had certain recent treatments.
This study tests a new drug called SHR-2173 to help people with generalized myasthenia gravis (a condition where muscles weaken because the immune system blocks communication between nerves and muscles). The drug is designed to work with treatments you're already taking to improve muscle strength and reduce symptoms.
This study follows patients with generalized myasthenia gravis (a condition where muscles weaken over time) who have specific antibodies and are being treated with rozanolixizumab, a medication that helps reduce symptom severity. Researchers will monitor how symptoms change in real-world settings.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.